Effect of inhaled tiotropium on patients with COPD.
- Author:
Yang Il KANG
1
;
Tae Jun NOH
;
Hye Sook CHOI
;
Cheon Woong CHOI
;
Myung Jae PARK
;
Hong Mo KANG
;
Jee Hong YOO
Author Information
1. Department of Pulmonary and Critical Care Medicine, Kyung Hee University College of Medicine, Seoul, Korea. honglung@chol.com
- Publication Type:Original Article
- Keywords:
Chronic obstructive pulmonary disease;
Tiotropium;
St George's respiratory questionnaire;
MRC dyspnea scale;
Lung function
- MeSH:
Dyspnea;
Humans;
Inspiratory Capacity;
Lung;
Motor Activity;
Pulmonary Disease, Chronic Obstructive*;
Quality of Life;
Residual Volume;
Respiratory Function Tests;
Tiotropium Bromide;
Surveys and Questionnaires
- From:Korean Journal of Medicine
2007;73(2):159-168
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Tiotropium is a long acting anticholinergic bronchodilator and it reduces exacerbations and improves the quality of life of patients with stable chronic obstructive pulmonary disease (COPD). The purpose of this study was to evaluate the effect of tiotropium on dyspnea, the quality of life and the pulmonary function in patients with COPD. METHODS: Between April 2005 and April 2006, the patients with moderate to severe COPD, as based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, and who needed to use long-acting bronchodilator were enrolled in this study. They inhaled tiotropium as a dry powder capsule, 18 microgram once daily for six months, with using the Handihaler(R) device. The lung function tests, including lung volume, the St. George's respiratory questionnaire and the MRC dyspnea scale, was measured at baseline and after 6 months treatment with tiotropium. RESULTS: 21 patients with COPD were enrolled. The mean age of the patients was 69 years and the mean baseline FEV1 was 1.0 L (40% predicted). Compared with the baseline, tiotropium produced significant improvement of the FEV1 (1.0+/-0.2 L vs. 1.1+/-0.3 L, respectively, p=0.013), IC (1.65+/-0.3 L vs. 1.7+/-0.3 L, respectively, p=0.037), the RV (4.0+/-0.7 L vs. 3.8+/-0.4, respectively, p=0.003), the SGRQ score (48.7+/-10 vs. 41.3+/-10.4, respectively, p<0.001), and the MRC dyspnea scale (3.4+/-0.6 vs. 3.0+/-0.8, respectively, p=0.009) after 6 months treatment. The dyspnea scale was associated with physical activity, the impact on life, the inspiratory capacity and the residual volume rather than the symptom score or FEV1. The treatment was well tolerated. CONCLUSIONS: Treatment with tiotropium once daily for 6 months improved lung functions, the health related quality of life and dyspnea.
